Advancing HFpEF Treatment with Novel MRAs - Episode 12
MRA Combination Therapies and Monitoring in HFpEF
Discussion centers on combining MRAs with other agents while maintaining vigilant monitoring to minimize risks and optimize long-term management.
Panelists discussed how combining mineralocorticoid receptor antagonists (MRAs) with other evidence-based therapies can provide synergistic benefits in heart failure with preserved ejection fraction (HFpEF) management. Nonsteroidal MRAs, in particular, pair well with sodium-glucose transporter 2 inhibitors and angiotensin receptor neprilysin inhibitors, helping reduce fibrosis, inflammation, and fluid overload.
The group emphasized that effective combination therapy depends on regular monitoring. Tracking potassium levels, renal function, and blood pressure is essential to prevent complications. They highlighted the need for clear follow-up plans and patient education to ensure adherence.
Ultimately, combining therapies in a strategic, individualized way can improve long-term outcomes. Panelists agreed that balancing efficacy with safety remains the foundation of successful HFpEF treatment.
